Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
GlaxoSmithKline ( (GB:GSK) ) has shared an announcement.
GlaxoSmithKline (GSK) has announced the purchase of 476,537 of its own ordinary shares, as part of its ongoing buyback program. The shares, bought at prices ranging from 1,403.50p to 1,421.50p, will be held as treasury shares. This move is part of a non-discretionary agreement with Merrill Lynch International, which has been in effect since June 4, 2025. Following this transaction, GSK holds 224,237,962 shares in treasury, which represents 5.48% of the company’s voting rights. This buyback initiative is likely aimed at consolidating GSK’s market position and optimizing shareholder value.
The most recent analyst rating on (GB:GSK) stock is a Buy with a £22.90 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.
Spark’s Take on GB:GSK Stock
According to Spark, TipRanks’ AI Analyst, GB:GSK is a Outperform.
GSK’s overall stock score is driven by strong financial performance, positive earnings call outcomes, and strategic corporate actions like share buybacks. While technical indicators show weak momentum, the stock’s valuation and promising corporate events enhance its attractiveness.
To see Spark’s full report on GB:GSK stock, click here.
More about GlaxoSmithKline
Average Trading Volume: 10,285,780
Technical Sentiment Signal: Hold
Current Market Cap: £56.8B
For detailed information about GSK stock, go to TipRanks’ Stock Analysis page.